AbCellera Biologics Inc. said Monday that terms of its initial public offering have been set, which could value the artificial intelligence (AI)-powered drug discovery company at up to $4.52 billion. The Vancouver-based company, which is working with Eli Lilly & Co. on a COVID-19 therapy, said it is offering 23 million shares in the IPO, which is expected to price between $14 and $17 a share, which means the company could raise as much as $391 million. The company expects to have 265.95 million shares outstanding after the IPO.